November 26th 2024
Operating in an aging facility and/or utilizing outdated equipment may lead to drug shortages and high operating costs.
Sartorius Stedim Biotech and Repligen Corporation Partner to Introduce Perfusion-Enabled Bioreactors
September 4th 2018A collaboration integrates Sartorius Stedim Biotech’s BIOSTAT STR bioreactors and Repligen’s XCell ATF cell-retention control technology to create simplified, scalable equipment for intensified cell culture.
Sartorius Supports ABL Europe in Viral Vector GMP Capacity Expansion
March 19th 2018Sartorius has delivered to ABL’s Strasbourg facility, a GMP viral vector manufacturing package solution that includes single-use bioreactors and an automation platform for normal flow filtration, tangential filtration, and mixing.